Mirum Pharmaceuticals (MIRM) EBITDA (2019 - 2026)

Mirum Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at -$789.5 million for Q1 2026.

• In Q1 2026, EBITDA fell 5099.66% year-over-year to -$789.5 million; the TTM figure through Mar 2026 stood at -$796.4 million (down 943.51% YoY), while the FY2025 annual figure was -$22.1 million, up 74.73% from the prior year.
• EBITDA was -$789.5 million for Q1 2026 at Mirum Pharmaceuticals, down from -$4.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.6 million in Q3 2025 to a low of -$789.5 million in Q1 2026.
• Historically, EBITDA has averaged -$67.0 million across 5 years, with a median of -$25.1 million in 2023.
• The sharpest annual moves came in 2025 and 2026: EBITDA soared 120.52% in 2025, then slumped 5099.66% in 2026.
• A 5-year view of EBITDA shows it stood at -$34.2 million in 2022, then increased by 4.61% to -$32.6 million in 2023, then advanced by 25.67% to -$24.2 million in 2024, then soared by 81.15% to -$4.6 million in 2025, then plunged by 17186.29% to -$789.5 million in 2026.
• The last three EBITDA figures came in at -$789.5 million (Q1 2026), -$4.6 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.